Equities analysts expect that Teva Pharmaceutical Industries Ltd (NYSE:TEVA) will post earnings of $0.56 per share for the current quarter, Zacks reports. Seven analysts have made estimates for Teva Pharmaceutical Industries’ earnings, with estimates ranging from $0.43 to $0.68. Teva Pharmaceutical Industries posted earnings per share of $0.93 in the same quarter last year, which indicates a negative year-over-year growth rate of 39.8%. The firm is expected to announce its next earnings report on Thursday, February 14th.
According to Zacks, analysts expect that Teva Pharmaceutical Industries will report full year earnings of $2.93 per share for the current fiscal year, with EPS estimates ranging from $2.80 to $3.03. For the next fiscal year, analysts forecast that the firm will post earnings of $2.80 per share, with EPS estimates ranging from $2.20 to $3.30. Zacks’ EPS calculations are a mean average based on a survey of research analysts that follow Teva Pharmaceutical Industries.
Teva Pharmaceutical Industries (NYSE:TEVA) last posted its earnings results on Thursday, November 1st. The company reported $0.64 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.53 by $0.11. The company had revenue of $4.53 billion for the quarter, compared to analyst estimates of $4.54 billion. Teva Pharmaceutical Industries had a negative net margin of 54.67% and a positive return on equity of 21.83%. The business’s revenue for the quarter was down 19.4% compared to the same quarter last year. During the same period last year, the business posted $1.00 earnings per share.
TEVA has been the topic of a number of research analyst reports. Zacks Investment Research upgraded shares of Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating and set a $24.00 price objective on the stock in a report on Monday, December 3rd. Maxim Group restated a “hold” rating on shares of Teva Pharmaceutical Industries in a report on Thursday, November 1st. Royal Bank of Canada set a $22.00 price objective on shares of Teva Pharmaceutical Industries and gave the stock a “hold” rating in a report on Friday, November 2nd. Oppenheimer restated a “hold” rating on shares of Teva Pharmaceutical Industries in a report on Wednesday, November 7th. Finally, Wells Fargo & Co restated a “hold” rating on shares of Teva Pharmaceutical Industries in a report on Friday, November 2nd. Two analysts have rated the stock with a sell rating, fourteen have assigned a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. Teva Pharmaceutical Industries presently has a consensus rating of “Hold” and a consensus price target of $22.15.
TEVA opened at $18.45 on Friday. The company has a current ratio of 0.94, a quick ratio of 0.61 and a debt-to-equity ratio of 1.75. The firm has a market capitalization of $18.26 billion, a price-to-earnings ratio of 4.69, a PEG ratio of 5.71 and a beta of 1.10. Teva Pharmaceutical Industries has a twelve month low of $14.59 and a twelve month high of $25.96.
In related news, VP Hafrun Fridriksdottir sold 1,643 shares of the firm’s stock in a transaction on Wednesday, January 2nd. The shares were sold at an average price of $15.70, for a total value of $25,795.10. Following the completion of the transaction, the vice president now owns 13,469 shares of the company’s stock, valued at $211,463.30. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In the last ninety days, insiders sold 2,922 shares of company stock valued at $53,962. 0.43% of the stock is owned by insiders.
Several institutional investors and hedge funds have recently made changes to their positions in TEVA. FMR LLC grew its position in shares of Teva Pharmaceutical Industries by 19.1% in the 3rd quarter. FMR LLC now owns 24,481,936 shares of the company’s stock valued at $527,341,000 after acquiring an additional 3,921,785 shares during the period. Beck Mack & Oliver LLC bought a new position in shares of Teva Pharmaceutical Industries in the 3rd quarter valued at about $64,484,000. Alliancebernstein L.P. grew its position in shares of Teva Pharmaceutical Industries by 32.0% in the 3rd quarter. Alliancebernstein L.P. now owns 9,454,839 shares of the company’s stock valued at $203,657,000 after acquiring an additional 2,291,171 shares during the period. Mckinley Capital Management LLC Delaware bought a new position in shares of Teva Pharmaceutical Industries in the 3rd quarter valued at about $33,272,000. Finally, Clal Insurance Enterprises Holdings Ltd grew its position in shares of Teva Pharmaceutical Industries by 168.5% in the 3rd quarter. Clal Insurance Enterprises Holdings Ltd now owns 1,814,219 shares of the company’s stock valued at $39,078,000 after acquiring an additional 1,138,423 shares during the period. 61.66% of the stock is owned by institutional investors.
About Teva Pharmaceutical Industries
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.
Further Reading: Systematic Risk
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.